Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

Press Releases

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
Keyword Search
 
2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
12/03/12Alkermes and Collaborators to Present Data from Three Ongoing Clinical Development Programs at Two Major Medical MeetingsPrinter Friendly Version
11/07/12Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
11/01/12Alkermes plc Reports Second Quarter Fiscal 2013 Financial ResultsPrinter Friendly Version
10/25/12Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2013Printer Friendly Version
09/25/12Alkermes plc Closes Debt Refinancing, Lowering Interest Rate and Reducing Principal AmountPrinter Friendly Version
09/19/12Alkermes plc Announces Pricing of New Term LoansPrinter Friendly Version
08/30/12Alkermes’ Corporate Presentation to Be Webcast at Two Upcoming ConferencesPrinter Friendly Version
07/26/12Alkermes plc Reports First Quarter Fiscal 2013 Financial ResultsPrinter Friendly Version
07/19/12Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2013Printer Friendly Version
06/12/12INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for SchizophreniaPrinter Friendly Version
06/09/12BYDUREON™ Was Associated with Significant and Sustained Glycemic Control at Four YearsPrinter Friendly Version
06/09/12BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 DiabetesPrinter Friendly Version
06/09/12Once-Weekly BYDUREON™ Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir® in Type 2 DiabetesPrinter Friendly Version
05/31/12Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
05/30/12Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced ConstipationPrinter Friendly Version
05/29/12Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit MeetingPrinter Friendly Version
05/17/12Alkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013Printer Friendly Version
05/10/12Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2012Printer Friendly Version
05/03/12VIVITROL(R) Data to be Presented at Upcoming American Psychiatric Association Annual MeetingPrinter Friendly Version
03/13/12Alkermes plc Completes Secondary Offering of 24,150,000 Ordinary Shares Held by ElanPrinter Friendly Version
03/08/12Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by ElanPrinter Friendly Version
03/07/12Alkermes plc Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by ElanPrinter Friendly Version
03/05/12Alkermes Appoints Mark Stejbach as Chief Commercial OfficerPrinter Friendly Version
02/27/12Alkermes’ Corporate Presentation to be Webcast at the Cowen & Company 32nd Annual Health Care ConferencePrinter Friendly Version
02/16/12Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder AgreementPrinter Friendly Version
02/13/12BYDUREON™, First and Only Once-Weekly Type 2 Diabetes Treatment, Now Available in U.S. Pharmacies Printer Friendly Version
02/09/12Alkermes' Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare ConferencePrinter Friendly Version
02/06/12Alkermes’ Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor ConferencePrinter Friendly Version
02/02/12Alkermes plc Reports Third Quarter Fiscal 2012 Financial ResultsPrinter Friendly Version
01/31/12Alkermes Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid DependencePrinter Friendly Version
01/27/12FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 DiabetesPrinter Friendly Version
01/26/12Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012Printer Friendly Version
01/04/12Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive DisorderPrinter Friendly Version
01/03/12Alkermes’ Corporate Presentation to be Webcast at the 30th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version